In colorectal, non-small-cell lung and breast cancer, the addition of bevacizumab to conventional chemotherapy has demonstrated some clinical benefit. Consequently, this drug has been approved by ...

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...

Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

The CAIRO5 trial confirmed the benefit of both two-drug chemotherapy regimens with bevacizumab instead of a three-drug ...

Cadonilimab plus chemotherapy, with or without bevacizumab, could be a safe and effective treatment option, according to researchers.

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer ...